Pacific Biosciences of California (NASDAQ:PACB) Posts Quarterly Earnings Results, Beats Estimates By $0.02 EPS

Pacific Biosciences of California (NASDAQ:PACB) posted its quarterly earnings data on Wednesday. The biotechnology company reported ($0.11) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.13) by $0.02, FiscalAI reports. The firm had revenue of $40.56 million during the quarter, compared to analysts’ expectations of $39.31 million. Pacific Biosciences of California had a negative net margin of 82.49% and a negative return on equity of 5,752.12%.

Here are the key takeaways from Pacific Biosciences of California’s conference call:

• SPRQ-Nx adoption is expanding: it accounted for over half of Revio consumable revenue, and two-thirds of the install base had upgraded by quarter-end. PacBio expects adoption to broaden further and sees the lower cost per genome supporting higher utilization and stronger pull-through over time.
• Clinical genomics and strategic partnerships are gaining traction. Clinical consumables grew more than 20% year over year, while GeneDx plans to add long-read sequencing and Berry Genomics ordered 10 Revio systems for a five-year rare-disease program; PacBio also highlighted collaborations involving biomedical AI and drug discovery.
• Growth remains modest and uneven: Q3 revenue rose 6% year over year to $40.6 million, while consumables revenue fell year over year to $20.8 million as customers used existing inventory and validated new workflows. PacBio narrowed full-year revenue guidance to $155 million–$160 million and cited ongoing academic and government funding constraints.
• Gross margin declined to 36% from 42% a year earlier, with higher memory costs and Vega manufacturing transition costs weighing on results. The company ended the quarter with $199.4 million in cash, and management acknowledged that strategic deals will take time to translate into meaningful revenue and cash generation.
• PacBio said its high-throughput platform remains on track for commercial launch by the end of 2027, with development fully resourced. It continues to target cash-flow breakeven in 2028, citing planned expense reductions, although that goal depends on executing its product roadmap and growing revenue.

Pacific Biosciences of California Trading Down 2.8%

Shares of Pacific Biosciences of California stock traded down $0.07 on Thursday, hitting $2.48. The stock had a trading volume of 12,472,291 shares, compared to its average volume of 8,301,978. Pacific Biosciences of California has a 52-week low of $1.07 and a 52-week high of $3.43. The company’s 50 day moving average price is $1.89 and its 200 day moving average price is $1.62. The stock has a market cap of $770.24 million, a price-to-earnings ratio of -5.78 and a beta of 2.21.

Wall Street Analyst Weigh In

Several equities research analysts recently weighed in on PACB shares. Piper Sandler reaffirmed a “neutral” rating and set a $3.00 target price (up from $2.00) on shares of Pacific Biosciences of California in a research note on Thursday. Wall Street Zen cut shares of Pacific Biosciences of California from a “hold” rating to a “sell” rating in a research report on Saturday, August 8th. Weiss Ratings upgraded shares of Pacific Biosciences of California from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Tuesday, October 13th. Finally, UBS Group initiated coverage on Pacific Biosciences of California in a report on Wednesday, September 9th. They set a “neutral” rating and a $1.35 price target on the stock. One research analyst has rated the stock with a Buy rating, three have assigned a Hold rating and two have given a Sell rating to the company. According to MarketBeat.com, Pacific Biosciences of California presently has a consensus rating of “Reduce” and an average target price of $1.96.

Insiders Place Their Bets

In other Pacific Biosciences of California news, insider James Gibson, II sold 661,815 shares of the firm’s stock in a transaction on Tuesday, October 6th. The shares were sold at an average price of $3.11, for a total transaction of $2,058,244.65. Following the transaction, the insider directly owned 1,083,848 shares of the company’s stock, valued at approximately $3,370,767.28. This trade represents a 37.91% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Mark Van Oene sold 26,911 shares of the stock in a transaction that occurred on Monday, August 17th. The stock was sold at an average price of $1.13, for a total value of $30,409.43. Following the sale, the insider directly owned 2,705,853 shares of the company’s stock, valued at $3,057,613.89. The trade was a 0.98% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders own 3.70% of the company’s stock.

Key Stories Impacting Pacific Biosciences of California

Here are the key news stories impacting Pacific Biosciences of California this week:

• Positive Sentiment: For Q3 2026, PacBio reported a loss of $0.11 per share, better than the $0.13 loss analysts expected, while revenue of $40.56 million exceeded the $39.31 million consensus estimate. Zacks Q3 earnings report
• Positive Sentiment: A Q3 analysis pointed to clinical adoption and AI partnerships as contributors to steady growth, suggesting potential longer-term demand opportunities. Q3 clinical adoption and AI partnerships analysis
• Neutral Sentiment: PacBio narrowed its 2026 revenue guidance to $155 million–$160 million. A tighter range provides an updated outlook, but the article does not specify whether it represents a change in expected performance. Revenue guidance and cash-flow target
• Negative Sentiment: The company still posted a quarterly loss, and management is targeting cash-flow breakeven only in 2028, underscoring the time and execution required to reach sustainable finances. Cash-flow breakeven outlook

About Pacific Biosciences of California

Pacific Biosciences of California, Inc (NASDAQ: PACB) is a life sciences technology company that develops and supplies DNA sequencing systems, consumables and related software. The company is best known for its single-molecule, real-time (SMRT) sequencing technology, which produces highly accurate long-read data used to analyze complex genomes, structural variation, genetic disease and other biological information.

PacBio’s product portfolio includes the Revio long-read sequencing system, the Sequel II and Sequel IIe platforms, sequencing consumables and the associated data-analysis software.